B Braun Medical recalled 66,792 IV Administration Sets on October 29, 2025, due to a potential backflow risk. The recall affects models used with Infusomat Space, Outlook, and Vista Basic Pumps. Healthcare providers must stop using these devices immediately.
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact B Braun Medical Inc or your healthcare provider for instructions. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled IV Administration Sets include: 1. Catalog Number: 490241 (IV ADMIN SET HF STOPCOCK, 107 IN.) 2. Catalog Number: 490298 (IV ADMIN SET W/15 DROPS/ML, 116 IN.) 3. Catalog Number: 490360 (IV ADMIN SET, 15 DROP, 4 CARESITE, 119 IN.). These sets were distributed worldwide, including the US, Canada, Germany, Guatemala, and Singapore.
The recall stems from a potential for backflow of medication from secondary IV containers into primary IV containers. This issue may lead to medication errors and pose serious health risks.
As of now, there are no reported injuries or deaths associated with this recall. However, the hazard level is classified as high due to the serious implications of backflow.
Stop using the IV Administration Sets immediately. Follow the recall instructions provided by B Braun Medical. Contact your healthcare provider or B Braun Medical Inc for further instructions.
For more information, contact B Braun Medical Inc. Visit their website or call customer service for assistance.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.